10 Years of CAR-T
The fast and demonstrable, curative effects that several approved CAR-T therapeutics have had over the past decade have excited the advanced therapies and oncology communities, encouraging rapid research and development.
Since the approval of Kymriah by the FDA in August 2017 for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL), there have been seven CAR-T therapies approved and marketed around the world, across eight different conditions.
As of April 2022, in addition to these seven marketed therapies, six are pre-registered, eleven are at Phase III, 257 at Phase II and 371 at Phase I. As the pace accelerates within this area of development, challenges remain in ensuring the safe, cost-effective and time-critical manufacture of these patient-specific therapies.
For this feature, the Phacilitate team has invited experts working at different stages of the CAR-T development and commercialization journey to share their insights and experiences as we explore the last 10 years of CAR-T. Through dedicated interviews, blogs, articles, infographics and eBooks, we consider the strides CAR-T has made, the challenges that remain obstacles in the therapeutics’ commercialization journey, and what the future may hold for its development.
Use the slider below to navigate through content, and watch this space for updates as the month goes on.
If you would like to contribute to this feature, please contact the team via email@example.com